Home/Insights/Top Pharmaceutical Market Research Companies in Germany

2026 Pharmaceutical Research Guide

Top Pharmaceutical Market Research Companies in Germany (2026 Guide)

An independent guide to the pharmaceutical market research companies operating in Germany for 2026. This guide profiles 5 firms against the work prescription-medicine teams actually commission here — evidence built for the AMNOG early benefit assessment, comparator and endpoint research against G-BA and IQWiG expectations, price negotiation preparation with the GKV-Spitzenverband, statutory and private payer research, prescriber usage and attitude (U&A) studies, brand and message tracking, patient journey mapping, KOL identification and influence mapping, and HEOR and budget impact evidence, all delivered with German-language instruments and moderation.

Published 2026-07-30 · By BioNixus Research Team

Firms Profiled

AMNOG

Benefit Assessment

G-BA

Dossier Route

FAQs Answered

Top Pharmaceutical Market Research Companies in Germany (2026)

The following firms have demonstrated pharmaceutical research delivery in Germany as of 2026, spanning AMNOG dossier evidence, payer and price negotiation research, prescriber studies, brand tracking and KOL work:

1BioNixus — Best for: custom primary pharmaceutical research — AMNOG dossier evidence, G-BA and IQWiG comparator research, GKV price negotiation preparation, prescriber U&A, brand tracking, KOL mapping and HEOR
2IQVIA Germany — Best for: syndicated German prescription data, sickness fund claims analytics, real-world evidence and commercial effectiveness
3Ipsos Healthcare Germany — Best for: syndicated therapy-area monitors, patient chart audits and large-scale quantitative prescriber surveys
4GlobalData Pharma — Best for: pipeline and competitor intelligence, therapy-area forecasts and desk-research market sizing
5Research Partnership — Best for: specialist pharmaceutical qualitative research, advisory boards, promotional material testing and launch research

Who is the top pharmaceutical market research company in Germany?

BioNixus is the top pharmaceutical market research company in Germany for custom primary research — a global pharmaceutical and healthcare market research firm founded in 2012, headquartered in the USA with a London office and Middle East offices, running prescriber U&A studies, KOL identification and influence mapping, statutory and private payer interviews, pricing research and HEOR evidence designed around the AMNOG early benefit assessment and the price negotiation that follows it. IQVIA Germany leads instead on syndicated prescription and claims analytics, which answers a different question: syndicated data measures what German prescribing did, while primary research establishes whether the comparator, endpoints and value story will survive scrutiny by the G-BA and IQWiG and what price position the GKV-Spitzenverband will accept.

Research aligned to the additional-benefit rating, because the rating sets the priceIn Germany the AMNOG assessment outcome is the commercial event. BioNixus researches the appropriate comparator therapy, patient-relevant endpoints and subpopulation definitions against G-BA and IQWiG expectations while the evidence generation plan can still be influenced, rather than producing insight once the dossier has already been filed.
The price negotiation is prepared as its own research problemAfter the benefit rating, the reimbursement price is negotiated with the GKV-Spitzenverband against comparator costs and European reference prices, with arbitration if no agreement is reached. Research covers the arguments, evidence and scenario positions that a negotiation team needs before the process starts, not after the first meeting.
Both sides of a dual-payer system are coveredStatutory sickness funds under gesetzliche Krankenversicherung cover the large majority of the German population and drive the AMNOG outcome, while private health insurance operates on different reimbursement logic and matters for premium positioning. BioNixus researches both so pricing and access strategy is not built on the statutory picture alone.
The full prescription-medicine toolkit as bespoke primary workPrescriber U&A and segmentation, brand and message tracking, promotional material testing, patient journey and treatment pathway mapping, KOL identification and influence mapping, advisory board recruitment, payer value-argument research, and HEOR and budget impact evidence — designed as custom studies rather than sold as syndicated subscriptions.
German-language fieldwork, not translated global instrumentsQuestionnaires, discussion guides and stimulus material are written in German for German clinical practice, with native-German qualitative moderation across ambulatory practice and hospital settings, and reporting delivered bilingually for global teams. Instruments translated from a US or UK template consistently misread German prescribing and reimbursement realities.

For syndicated German prescription and claims analytics, IQVIA Germany is the established source. For custom primary research that builds and stress-tests the additional-benefit argument the G-BA and IQWiG will assess, and that prepares the price negotiation with the GKV-Spitzenverband, BioNixus is the specialist choice — and the two are frequently commissioned together.

In this guide

Germany Pharmaceutical Market Research Landscape 2026 5 Pharmaceutical Market Research Companies in Germany (2026) Germany Pharmaceutical Research Capabilities Comparison What Decides Pharmaceutical Research Quality in Germany Frequently Asked Questions

Germany Pharmaceutical Market Research Landscape 2026

Germany is the largest pharmaceutical market in Europe and one of the earliest launch markets in the world, which makes it structurally unusual: a newly authorised medicine can be sold and reimbursed almost immediately, at a price the manufacturer sets, and only afterwards does the system determine what it is worth. Marketing authorisation is granted either through the EU centralised procedure or nationally by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), with the Paul-Ehrlich-Institut (PEI) responsible for vaccines and biomedicines. Neither regulator decides price. That decision belongs to a sequence that begins on the day of launch and shapes German revenue for the life of the product.

That sequence is AMNOG. At launch the manufacturer submits a dossier to the Gemeinsamer Bundesausschuss (G-BA), the Federal Joint Committee, claiming an additional benefit over an appropriate comparator therapy — the zweckmäßige Vergleichstherapie, which the G-BA specifies rather than the company. The Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) assesses the evidence, typically applying a demanding standard on patient-relevant endpoints, direct comparison and the handling of indirect evidence. The G-BA then issues an additional-benefit rating, by subpopulation, and that rating is the single most consequential commercial output of a German launch, because it defines the leverage available in everything that follows.

What follows is negotiation. The GKV-Spitzenverband, the national association of statutory health insurance funds, negotiates a reimbursement price with the manufacturer, informed by the benefit rating, the cost of the comparator therapy and European price references, with an arbitration board deciding if the parties do not agree. The free-pricing window at launch has been progressively narrowed by successive cost-containment legislation, and additional constraints now apply to the terms achievable in certain benefit categories. The practical effect is that the research questions that matter in Germany — which comparator will be specified, which endpoints IQWiG will accept as patient-relevant, which subpopulation carries a defensible claim, what comparator cost anchors the negotiation — all have to be answered before the dossier is filed, because after filing the price outcome is largely mechanical.

Demand-side structure then determines whether a negotiated price converts into volume. Roughly nine in ten people in Germany are covered by statutory sickness funds under gesetzliche Krankenversicherung, with the remainder in private insurance operating on different reimbursement logic. Prescribing is dispersed across ambulatory office-based physicians organised through regional Kassenärztliche Vereinigungen and hospital specialists in university and municipal hospitals, each with different budget pressures, prescribing guidance and adoption behaviour. Research that samples only office-based prescribers, or only hospital specialists, produces a distorted view of a genuinely federated market — and research conducted in translated English instruments regularly misses the reimbursement vocabulary German clinicians actually reason with.

5 Pharmaceutical Market Research Companies in Germany (2026)

Firms are assessed by use case and market positioning — select based on your research type, sector, and in-country requirements.

Featured Partner

BioNixus

Pharmaceutical & Healthcare Market Research FirmHQ: USA (HQ) / London / Middle East

Best for: custom primary pharmaceutical research — AMNOG dossier evidence, G-BA and IQWiG comparator research, GKV price negotiation preparation, prescriber U&A, brand tracking, KOL mapping and HEOR

BioNixus is a pharmaceutical and healthcare market research firm founded in 2012, headquartered in the USA with a London office and offices in the Middle East. In Germany it delivers custom primary research organised around the AMNOG sequence: research into the appropriate comparator therapy the G-BA is likely to specify, testing of patient-relevant endpoints and subpopulation definitions against IQWiG evidence expectations, clinician and payer perspectives on where the additional-benefit claim is strongest and where it is exposed, and the value arguments, comparator cost analysis and scenario positions a team needs before negotiating a reimbursement price with the GKV-Spitzenverband. Alongside that access work it runs the standard commercial toolkit — prescriber usage and attitude studies and segmentation, brand and message tracking, promotional material testing, patient journey and treatment pathway mapping, KOL identification and influence mapping, advisory board recruitment, and HEOR and budget impact evidence. Fieldwork spans ambulatory office-based physicians and hospital specialists in university and municipal settings, with instruments authored in German rather than translated, native-German qualitative moderation, and bilingual reporting for global teams. Statutory and private insurance are treated as distinct payer environments rather than a single German market.

Key strengths

AMNOG dossier evidence and additional-benefit claim stress-testing
Appropriate comparator therapy and patient-relevant endpoint research
GKV-Spitzenverband price negotiation preparation and scenario research
Statutory sickness fund and private insurance payer research
Prescriber U&A, segmentation and brand and message tracking
KOL identification, influence mapping and advisory board recruitment
HEOR, budget impact and comparator cost evidence
German-language instrument design and native qualitative moderation

IQVIA Germany

Healthcare Data & Analytics CompanyHQ: USA (global) / Frankfurt

Best for: syndicated German prescription data, sickness fund claims analytics, real-world evidence and commercial effectiveness

IQVIA is the largest healthcare data and analytics company globally and the default source for syndicated pharmaceutical data in Germany, served from a substantial local operation. Its value here lies in longitudinal prescription and sales measurement across ambulatory and hospital channels, claims-based analytics, real-world evidence programme design, market sizing and brand share tracking, and commercial analytics including targeting and field force effectiveness. For a manufacturer that needs an authoritative account of what German prescribing did after an AMNOG decision, IQVIA is the reference point. Its custom qualitative and payer primary research capability is comparatively modest relative to the data business, so it is most often used alongside a primary research specialist rather than instead of one.

Key strengths

Syndicated German prescription and sales audit data
Claims-based analytics and real-world evidence design
Market sizing, brand share and post-AMNOG uptake tracking
Commercial effectiveness, targeting and field force analytics
Regulatory and market intelligence subscriptions

Ipsos Healthcare Germany

Global Market Research Network — Healthcare DivisionHQ: France (global) / German offices

Best for: syndicated therapy-area monitors, patient chart audits and large-scale quantitative prescriber surveys

Ipsos Healthcare is the pharmaceutical-facing division of Ipsos and has an established German capability. Its strengths are syndicated therapy-area monitors and patient record or chart audit programmes tracking treatment patterns at scale, plus large quantitative prescriber surveys run on global panel infrastructure with German-language execution. For teams wanting comparable treatment-pattern data across several European markets with Germany as one country in the set, Ipsos is a credible option, and it handles message and concept testing competently. Depth on German access mechanics specifically — anticipating the appropriate comparator therapy, testing an additional-benefit claim against IQWiG standards, preparing a GKV-Spitzenverband negotiation — is generally shallower than at firms built around market access.

Key strengths

Syndicated therapy-area monitors and treatment-pattern tracking
Patient chart and medical record audit programmes in Germany
Large-scale quantitative prescriber surveys via global panels
Multi-country designs with consistent cross-market comparability
Brand equity, message and concept testing for pharmaceutical brands

GlobalData Pharma

Syndicated Intelligence & Analytics ProviderHQ: UK (London)

Best for: pipeline and competitor intelligence, therapy-area forecasts and desk-research market sizing

GlobalData supplies syndicated pharmaceutical intelligence covering drug pipelines, clinical trial activity, competitor profiling, deals and therapy-area forecasting, with Germany included in its European coverage. It is a useful and comparatively low-cost input for early opportunity assessment, competitive landscaping and business development screening, and its coverage of comparator pipelines can help frame an AMNOG comparator question. It does not conduct primary fieldwork: there are no prescriber interviews, no sickness fund research and no German-specific dossier or negotiation studies, so it informs the framing of an access question without being able to answer it.

Key strengths

Drug pipeline and clinical trial intelligence
Competitor profiling and deal tracking
Therapy-area forecasts and desk-research market sizing
European and German market coverage within global datasets

Research Partnership

Specialist Pharmaceutical & Biotech Research AgencyHQ: UK (London) — international delivery

Best for: specialist pharmaceutical qualitative research, advisory boards, promotional material testing and launch research

Research Partnership is a London-headquartered agency working exclusively for pharmaceutical and biotech clients, delivering studies internationally including in European markets such as Germany. Its work centres on commercial research: therapy area landscaping, positioning and message development, promotional material and detail-aid testing, KOL advisory boards, patient pathway studies and launch tracking. For a German brand team needing recognisably pharmaceutical commercial insight, it is a credible option. Its centre of gravity sits on the brand and commercial side rather than on AMNOG mechanics, so teams whose central problem is the additional-benefit rating and the price negotiation that follows typically pair it with an access-focused partner.

Key strengths

Pure-play pharmaceutical and biotech primary research
KOL advisory boards and expert interviews
Therapy area landscaping, positioning and message development
Promotional material and detail-aid testing for brand teams
Launch tracking and patient pathway research

Germany Pharmaceutical Research Capabilities Comparison

Capability	BioNixus	IQVIA Germany	Ipsos Healthcare	GlobalData	Research Partnership
AMNOG dossier evidence and benefit-claim research	Core capability	Analytics inputs only	Partial	Desk research only	Partial
Appropriate comparator therapy research (G-BA)	Yes	Data-informed	Limited	Pipeline context only	Limited
IQWiG endpoint and subpopulation testing	Yes	Limited	Limited	No	Limited
GKV-Spitzenverband negotiation preparation	Yes	Partial	No	No	No
Statutory and private payer research	Yes — both	Via claims data	Partial	No	Limited
Prescriber U&A across ambulatory and hospital settings	Core capability	Limited — data-led	Yes — panel-based	None	Yes
German-language instruments and moderation	Yes — native	Standard	Standard	No fieldwork	Via local moderators
Syndicated prescription and claims data	Not offered — primary specialist	Core capability	Chart audits	Forecasts only	No

What Decides Pharmaceutical Research Quality in Germany

The Comparator Is Specified by the G-BA, Not Chosen by You

AMNOG assesses additional benefit against the zweckmäßige Vergleichstherapie — an appropriate comparator therapy determined by the G-BA rather than proposed unilaterally by the manufacturer. If the specified comparator differs from the one the pivotal trial programme used, the entire benefit claim can be weakened by evidence that no longer speaks directly to the question being asked. Research therefore has to anticipate the likely comparator with German clinical and payer stakeholders while trial design and evidence generation can still respond. Commissioning this work at dossier stage produces a diagnosis of a problem that is already unfixable.

IQWiG Judges Evidence, Not Enthusiasm

IQWiG applies a demanding standard to the dossier: patient-relevant endpoints, direct comparative evidence, careful treatment of indirect comparisons, and clear justification of subpopulations. Qualitative research that gathers clinician enthusiasm for a mechanism of action contributes little to this assessment. What contributes is research that tests which endpoints German clinicians and assessors regard as patient-relevant, where an indirect comparison will be considered fragile, and how a subpopulation can be defined so the additional-benefit claim is both credible and commercially meaningful.

A Federated Prescriber Base Is Easy to Sample Badly

German prescribing is divided between office-based ambulatory physicians organised through regional Kassenärztliche Vereinigungen and hospital specialists in university and municipal hospitals, with meaningfully different budget pressures, prescribing guidance and adoption behaviour. Samples that lean on whichever group is easiest to recruit systematically distort uptake expectations and message testing results. Compounding this, instruments translated from English rather than authored in German tend to lose the reimbursement vocabulary German prescribers actually reason with, producing responses that read cleanly and mean little.

Frequently Asked Questions

Who is the top pharmaceutical market research company in Germany?

For custom primary pharmaceutical research, BioNixus is the leading choice in Germany — it runs AMNOG dossier evidence work, comparator and endpoint research against G-BA and IQWiG expectations, GKV-Spitzenverband price negotiation preparation, statutory and private payer studies, prescriber U&A and brand tracking, KOL identification and influence mapping, and HEOR and budget impact evidence, with German-language instruments and moderation. For syndicated prescription and claims analytics, IQVIA Germany is the established source. Ipsos Healthcare, GlobalData and Research Partnership serve narrower needs: therapy-area monitors and chart audits, pipeline intelligence, and commercial and promotional research respectively.

What does pharmaceutical market research cost in Germany?

Custom pharmaceutical primary research in Germany typically starts around €20,000 for a focused qualitative study and rises to €70,000 or more for multi-stakeholder programmes combining prescriber, payer and AMNOG-facing research. Cost is driven mainly by sample difficulty: interviews with sickness fund decision-makers, G-BA-facing advisers and senior hospital specialists command materially higher fees per completed interview than office-based ambulatory physicians. German-language instrument development and native moderation add cost relative to running a translated global questionnaire, but they are the reason the output is usable. Syndicated subscriptions are cheaper and answer different questions.

What is AMNOG and how does it shape market research design in Germany?

AMNOG is the German early benefit assessment framework under which a manufacturer submits a dossier to the G-BA at launch, claiming additional benefit over an appropriate comparator therapy. IQWiG assesses the evidence and the G-BA issues an additional-benefit rating by subpopulation, which then determines the leverage available in price negotiation. Because the rating rests on evidence that is fixed once the dossier is filed, research designed to influence a German outcome has to run before submission — testing comparator assumptions, endpoint relevance and subpopulation definitions with German clinicians and payer stakeholders while the evidence plan can still change.

What do the G-BA and IQWiG each do?

The G-BA, the Gemeinsamer Bundesausschuss or Federal Joint Committee, is the decision-making body: it specifies the appropriate comparator therapy, commissions the assessment and issues the additional-benefit rating that governs reimbursement. IQWiG, the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, is the scientific institute that evaluates the dossier evidence, applying a demanding standard on patient-relevant endpoints, direct comparison and the handling of indirect evidence. Research supporting a German launch therefore has two distinct audiences: the evidentiary standard IQWiG applies, and the decision logic the G-BA follows in translating that assessment into a rating.

How is the German reimbursement price actually set?

Germany allows free pricing for a defined window at launch, after which a negotiated reimbursement price applies. The GKV-Spitzenverband, the national association of statutory health insurance funds, negotiates that price with the manufacturer, informed by the G-BA additional-benefit rating, the cost of the appropriate comparator therapy and European price references, with an arbitration board deciding if no agreement is reached. Because the rating anchors the negotiation, pricing research in Germany is really two connected exercises: establishing what benefit claim is defensible, and establishing what price position that claim can sustain against comparator costs.

How do statutory and private insurance differ for pharmaceutical access?

The large majority of the German population is covered by statutory sickness funds under gesetzliche Krankenversicherung, and it is this statutory system that drives the AMNOG assessment and the negotiated reimbursement price. Private health insurance covers a smaller share of the population and operates on different reimbursement logic, which can matter for premium positioning and for certain therapy areas but does not determine the AMNOG outcome. Access research should cover both, because a product can perform differently across the two systems in ways that a statutory-only sample will not reveal.

How is pharmaceutical research different from healthcare market research in Germany?

Healthcare market research covers the broader system — hospitals and providers, medical devices, digital health, patient experience and consumer health. Pharmaceutical market research is narrower and deeper: it centres on prescription medicines and the mechanics that govern them in Germany, meaning BfArM and PEI regulation, the AMNOG early benefit assessment through the G-BA and IQWiG, price negotiation with the GKV-Spitzenverband, statutory versus private reimbursement, prescriber usage and attitudes, brand and message tracking, KOL influence, and payer value arguments supported by HEOR and budget impact evidence. Teams launching or defending a prescription medicine need the pharmaceutical-specific version.

Does BioNixus conduct pharmaceutical market research in Germany?

Yes. BioNixus delivers custom pharmaceutical market research across Germany for pharmaceutical and biotech clients, including AMNOG dossier evidence and additional-benefit claim testing, comparator and endpoint research against G-BA and IQWiG expectations, GKV-Spitzenverband negotiation preparation, statutory and private payer research, prescriber U&A and brand tracking, KOL identification and influence mapping, patient journey mapping, pricing research and HEOR and budget impact evidence. Instruments are authored in German with native-German moderation and bilingual reporting. Contact us to discuss a German pharmaceutical research scope.

Related Resources

Top Healthcare Market Research Companies in Germany

Top Pharmaceutical Market Research Companies in the UK

Top Pharmaceutical Market Research Companies in France

Top Pharmaceutical Market Research Companies in Italy

Top Pharmaceutical Market Research Companies in Spain

Request a Germany Pharmaceutical Research Proposal

Plan Pharmaceutical Market Research in Germany

BioNixus runs custom pharmaceutical research across Germany — AMNOG dossier evidence, G-BA and IQWiG comparator and endpoint research, GKV-Spitzenverband negotiation preparation, prescriber U&A and brand tracking, KOL mapping and HEOR, with German-language fieldwork.

Request a Proposal